Introduction
While a considerable amount of data-has been generated regarding chemotherapeutic and vaccine-based strategies for prevention or control of human immunodeficiency virus (HIV) infection, the human T-Iymphotropic viruses types I and II (HTLV-I, II) have attracted less attention worldwide. HIV-1 infection threatens the lives of an estimated 10 million globally according to "'le World Health Organization, and results in close to 100% mortality (Brookmeyer, 1991) . In contrast, the cumulative lifetime risks of an HTLV-I infected individual acquiring either HTLV-I-associated adult-T-cell leukaemia/lymphoma or the neurological degenerative syndrome HTLV-I-assoelated myelopathy/tropical spastic paraparesis (HAM/ TSP) are 1-5% and 0.25% respectively. Moreover, no consistent relationship between HTLV-II infection and human disease has been defined, although associations with a T-cell variant of hairy cell leukaemia have been reported (Kalyanaraman . et al., 1982; Rosenblatt et aI., 1987) . Yet HTLV-I and II infect over a million worldwide (Williams et al., 1988; Tajima etal., 1987; Hjelle etal., 1990) ;the former causing ã~~-~----------------~... -spectrum of primary and secondary diseases that rivals in complexity that of syphilis, tuberculosis, or HIV.
Elucidation of the genomic organization and regulatory mechanisms underlying HTLV gene expression and viral replication has provided a closer understanding not only of HTLV but of the human lentivirus HIV. Transactivating (tax, tat) gene products of HTLV and HIV, in concert with host-derived cellular factors, act on the promoter regions or long terminal repeats (LTR) of both viruses to increase transcription and viral expression (Sodroski et al., 1984; Montagne et al., 1990) , while the rex and rev regulatory molecules of these viruses, binding to complex viral RNA stem-loop structures, mediate differential splicing and expression of viral regulatory and structural genes (Malim et al., 1989; Ahmed et al., 1990) . Mechanisms of reverse transcription, proviral integration, viral expression, and other aspects of retroviral replication are similar for HTLV and HIV-1. However, the pathological sequelae are strikingly different: while HIV destroys the CD4+ T cell, HTLV-I transforms it. Human T-Iymphotropic viruses pose largely unmet challenges to researchers and clinicians who do not yet understand how HTLV transforms without a viral oncogene and who seek to intervene by designing strategies that target unique pathways of viral replication and pathogenesis.
The purpose of this brief review is to highlight the human T-Iymphotropic viruses and to emphasize their unique molecular characteristics and pathology as well as to provide a survey of antiviral strategies for HTLV-1. For a more in-depth analysis of HTLV molecular biology and pathogenesis, the reader is referred to Gallo and Nerurkar (1989) , Blattner (1990) , Cann and Chen (1990) , and Green and Chen (1990) .
Taxonomy
The human T-Iymphotropic viruses can be grouped according to nucleotide sequence homology with simian T-Iymphotropic virus (STLV) and bovine leukaemia virus (Ina and Gojobori, 1990) . This phylogenetic group is distinct from ungulate, non-human primate and human lentivlruses such as visna, simian immunodeficiency virus (SIV), and human immunodeficiency viruses types 1 and 2 (HIV-1 and 2), and distinct from the murine leukaemia and avian leukosis viruses (Doolittle et al., 1990) . Within the human leukaemia virus group, HTLV-I is more closely related to STLV (90-95% nucleotide sequence similarity) than to HTLV-II (60%) Watanabe et al., 1985) . Replication competent viruses within this group all contain, within their genomes, open reading frames encoding a transactivating (tax) protein that upregulates viral expression. No consistent correlation has been noted between nucleotide sequence variations among HTLV-I isolates and the spectrum of clinical sequelae associated with HTLV-I infection, suggesting that very subtle sequence variations might playa role in determining viral tropism and associated pathology (Ratner, 1990) .
Disease manifestations
Epidemiologic and molecular approaches have established a definite link between HTLV-I and adult T-cell leukaemia lymphoma (ATL). In the late 1970s, Takatsuki and co-workers (Uchiyama et al., 1977) first described a clustering of ATL in certain regions of southern Japan which were later found to be endemic for HTLV-1. Gallo, Poiesz and co-workers first identified HTLV-I virions in a T-cell line established from a patient with cutaneous T-cell lymphoma (Poiesz et al., 1980) , and similar viruses from Japanese ATL patients were soon isolated from transformed T-cell lines , Japanese and American isolates of HTLV-I were subsequently found to be essentially the same (Popovic et al., 1982; Watanabe et al., 1984) . Seroepidemiologic studies, restriction mapping, and sequencing of HTLV-I proviral isolates from around the world have since provided consistent evidence linking HTLV-I to ATL and HAMfTSP as well as to a spectrum of secondary diseases (Table 1) .
Clinical features of acute ATL include peripheral lymph node enlargement,_ hepatosplenomegaly, hypercalcaemia and skin lesions. White blood cell counts can range from normal to 500000. The surface phenotype of ATL cells is T3+ve, T4+ve, T8-ve, TAC+ve (IL-2 receptor a-chain). Although many different cell types Can be infected by HTLV-I in vitro, the CD4+ T-cell is the malignant cell type in ATL. Survival times range from 2 weeks to over 1 year after diagnosis. HTLV-I is also thought to be the initiating or causative agent of HAMfTSP (Imamura et al. 1988; Sarin et a7., 1989) , a neurological degenerative syndrome clinically associated with chronic spastic paraparesis, weakness of the lower limbs, bladder dysfunction, hyperreflexia of upper and lower limbs and other neurological abnormalities (Brew and Price, 1988; McFarlin and Koprowski, 1990; Rodgers-Johnson et al., 1990; Roman et al., 1990) .
Histopathologic studies of the spinal cord have revealed the presence of a chronic inflammatory reaction with demyelination and perivascular cuffing, especially in the posterior horns and peripheral nerve roots. It has been suggested that TSP is a result of an anti-HTLV-I autoimmune response (Sonada, 1990) , although HTLV-I might cause neurological disease by directly infecting the CNS (Liberski et al., 1988; Saida et al., 1988) . HAMfTSP has been identified in a transfusion recipient 5 months after receiving HTLV-I contaminated blood (Gout et al., 1990) . indicating a markedly shorter period between infection and disease than for ATL (10-30 years). Transfusion with HTLV-I infected blood has been identified as a risk factor for HAMfTSP in Japan . Four modes of HTLV-I transmission are widely recognized: breast feeding, blood transfusion, sexual intercourse, and intravenous drug abuse. Curtailing of breast feeding of children by HTLV-I+ve mothers has substantially reduced the incidence of mother-to-child transmission of HTLV-I in Japan (Ando et al., 1989; Tsuyi et al., 1990) . Screening of blood for anti-HTLV-I antibodies is also important for prevention of HTLV-I transmission (Nishimura et al., 1989) .
A second human retrovirus, HTLV-II is clinically associated with a variant oft-ceil hairy cell leukaemia, although a direct aetiologic link has yet to be confirmed (Kalyanaraman et al., 1982; Rosenblatt et al., 1987) . In the United States, HTLV-II is found in a significant percentage of intravenous drug abusers and New Mexico blood donors (Hjelle et aI., 1990) .
Molecular organization and viral structure
The proviral genome of HTLV-I ( Fig. 1a )is flanked at 5' and 3' .ends by a non-coding long terminal repeat or LTR divided into U3, R, and U5 regions (Seiki et al., 1983) . Regions within the LTR contain recognition sites for cellular proteins that in, concert with p40 tax (the tax gene product), upregulate viral expression (Brady et al., 1987; Montagne et al., 1990) . Cis-acting sequences responsive to tax (tax responsive elements, TRE) have been mapped
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to the U3 region of the 5' LTR (Brady et aI., 1987) , while the rex responsive element necessary for rex-regulated splicing of viral messages is present in the U3/region of the 3' LTR (HTLV-I) and the RlU5 region of the 5' LTR (HTLV-II) (Seiki et aI., 1988a; Ohta et al., 1988) .The U3 region of the HTLV LTR contains 3 copies of 21 base pair repeats which collectively serve as a transcriptional enhancer (Fujisawa et al., 1986; Brady et al., 1987) .These sites bear sequence homology to NF-KB and AP-1 sites as well as to a conserved cyclic AMP (cAMP) response element (Fujisawa et al., 1989; Poteat et aI., 1989; Tan et aI., 1989) . The LTR of HTLV-I can be activated by products of the proto-oncogenes c-jun (Jeang et al., 1991) and c-ets-t (Bosselut et al., 1990) , and by mitogens (Radonovich and Jeang, 1989) . As in other retroviruses, there are also regions in the LTRs of HTLV-I and II for binding of tRNA primers of negative strand DNA synthesis and a site for transfer of nascent 'strong-stop' DNA from 5' to 3' R regions during genomic replication.
The gag (group associated antigens) gene encodes a 53-55 kilodalton (kd) polyprotein precursor that is proteo-Iytically processed by a virally encoded protease (pro) to form smaller molecular weight proteins of 19, 24, and 15kd (Seiki et al., 1983) . A single genomic 8.5kb viral mRNA ( Fig. 1b ) encodes gag, pro, and pol in overlapping reading frames. There is evidence that a ribosomal frame shift accounts for synthesis of a 76 kd gag-pro precursor polyprotein that is autocatalytically cleaved by this cis acting viral protease (Nam et al., 1988) . A second frame shift is required for expression of the pol gene (Seiki et aI., 1983) .
The pro gene product, p14, mediates the maturational proteolysis of p55 gag and p76 gag-pro, although it has not been ruled out that cellular proteases cleave the p76 gag-pro precursor. The HTLV-I protease has a D':T-G sequence identical to that of aspartyl protease, and mutational analysis has revealed that the aspartic acid is required for proteolytic function (Nam et al., 1988) . Further data obtained with aspartyl protease inhibitors support the notion that this is an aspartyl protease (Katoh et al., 1987) .
The pol gene encodes a 95 kd reverse transcrlptase (RT) molecule with integrase and RNase H functions that are likely encoded by the 3' portion of the gene. The RT has a functional preference for Mg+ 2 over Mn+ 2 (Poiesz et aI., 1980) and mediates the replication of the single-stranded RNA genome into a double stranded DNA proviral form which integrates into random sites within host chromosomal DNA.
The env gene encodes a 63 kd envelope precursor which derives from a 4.2 kb, single-spliced viral message (Fig. 1b) entire envelope molecules can protect against HTLV-I infection of cynomolgus monkeys (Nakamura et al., 1987) and virus neutralizing epitopes have been mapped to regions within gp46 (Ralston et al., 1989; Palker, 1990; Tanaka et al., 1991) . A human monoclonal antibody to gp46, 0.5a (Matsushita et al., 1986) , can inhibit the mitogenic effect of UV-inactivated HTLV-I virions on resting human T-cells (Gazzolo and DucDodon, 1987) , indicating that gp46 may interact with T-cell surface molecules directly or indirectly linked to T-cell activation.
The gene for the HTLV-I receptor has been mapped to chromosome 17 (Sornrnerfelt et al., 1988) , although a specific gene product has not yet been identified. Immunogenic, HTLV-I specific sites recognized by antibodies (Copeland et el., 1986; Chen et al., 1989; Palker et al., 1989) and cytotoxic T cells (Jacobson et aI., 1991) from HTLV-I+ carriers have been mapped to specific regions of gp46. The N-terminus of p21 contains homology with immunosuppressive elements of other animal retroviruses (Cianciolo et al., 1984; Ruegg et al., 1989) but lacks a consensus hydrophobic F-L-G (phenylalanine-Ieucineglycine) fusion sequence frequently associated retroviralinduced syncytium·formation (Bosch et aI., 1989) . A 2.1 kb doubly spliced mRNA encodes both the tax and rex regulatory gene products in alternate reading frames (Seiki et al., 1985; Nagashima et al., 1986) . The tax (transactivator of transcription) gene products of HTLV-I and II are 40 and 36 kd molecules that localize to the nucleus and act in trans to activate viral transcription initiated from the LTR (Sodroski et al., 1984; Siamon et aI., 1988) . Tax does not bind directly to the 21 bp enhancer elements in the LTR but rather appears to associate with Human T-celllymphotropic viruses 131 Yamanashi et at. (1989) ) De Waal Malefyt et at. (1990 DNA by interacting with host DNA binding proteins (Montagne et aI., 1990) . The tax gene product is also capable of activating heterologous promoters of many genes involved in cell growth and differentiation (Table 2) .
Tax bears no homology to any known proto-oncogene and does not directly transform human T-cells. However, studies of tax expression in transgenic mice indicate that the effects of tax on cellular genes involved in gro~th and differentiation are likely to play a role in the multistep process of HTLV-I leukaemogenesis. Expression of tax from the HTLV-I promotor in transgenic mice results in induction of neurofibromas (Nerenberg et al., 1987) , which are non-lymphoid malignancies unlike HTLV-I associated adult T-cell leukaemia/lymphoma. However, tax expression in transgenic mice can also result in thymic atrophy (Furata et aI., 1989) , exocrine disorders like those seen in Sjogren's syndrome (Greene et aI., 1989b) and degeneration of oxidative muscle fibres (Nerenberg et aI., 1989) , which are all similar to pathological sequelae of HTLV-I infection in humans. In vitro, tax can also cooperate with ras to induce transformation (Pozzatti et sl., 1990) . Moreover, a herpes simplex virus vector expressing both tax and rex is capable of transforming mitogen activated cord blood cells (Grassman et al., 1989) . Thus, tax may playa significant role in disease induction and in leukaemogenesls, although the transformation process has not yet been defined.
The p27 rex gene product of HTLV-I derives from a 2.1 kb doubly spliced message and is localized in the -nucleolus of HTLV-I infected cells (Seiki et al., 1985; Malim et al., 1989) .A smaller p21 rex is also produced, although all functional rex activity can be attributed to p27 (Zazopoulos et al., 1990) . A proposed function of rex is to enhance transport of unspliced or partially spliced transcripts from the nucleus to the cytoplasm (Malim et al., 1989) . The net effect of high levels of rex expression is to induce the accumulation of gag and env mRNA expression of viral structural genes while diminishing levels of doubly spliced 2.1 kb viral mRNA encoding tax and rex (Yoshida et aI., 1988; Dokhelar et al., 1989) . This negative feedback mechanism allows rex-regulated viral gene expression to be divided into early and late phases . During the early phase, low levels of tax and rex are produced. In the late phase, increasing levels of rex favour cytoplasmic accumulation of unspliced or singly spliced message leading to viral structural gene expression, and a diminution of tax and rex expression. This tight regulation of gene expression could be critical for governing viral latency. Also, transient bursts of viral expression resulting from tax and rex-mediated regulation could effectively minimize immune surveillance by not allowing sufficient time for immune mediated clearance of infected cells (Green and Chen, 1990) .
Rex responsive elements have been localized to the U3/R region 3' LTR (HTLV-I) and the RlU5 region of the 5'LTR (HTLV-I) Seiki et al., 1988a) . Computer analysis indicates that these regions are capable of forming complex stem-loop structures (Malim et al., 1989; Ahmed et al., 1990) . Rex binds directly to this region and to a similar rev-responsive element of HIV-I (Bogerd et al., 1991) . HTLV-I rex can functionally replace the analogous HIV-I rev protein, although rev cannot functionally replace rex (Rimsky et aI., 1988; Sakai et al., 1990) .
Disease induction
The human T-Iymphotropic viruses lack the viral oncogenes of animal acute transforming retroviruses but contain an open reading frame between the env gene and 3'LTR which encodes the tax and rex regulatory genes. The tax gene product can transactivate genes for both IL-2 Siekevitz et a/., 1987) and the IL-2 receptor a-chain (Inoue et al., 1986; Siekevitz et al., 1987; Leung and Nabel, 1988) , establishing an autocrine growth loop that induces polyclonal proliferation of T-cells associated with random proviral integration. However, these events are not sufficient to induce direct transformation of T lymphocytes since IL-2 mRNA is present only in a minority of fresh leukaemic cells or HTLV-I transformed cell lines (Broder et al., 1984) . Polyclonal proliferation of HTLV-I infected T cells can be followed by outgrowth of a dominant transformed T-cell clone which contains monoclonally integrated proviral HTLV-I . However, the sites of monoclonal integration are not the same when HTLV-I transformed cells are compared from patient to patient (Seiki et a/., 1988b) . Thus, insertional cis-activation of cellular oncogenes by the viral LTR does not appear to be operative. Also, while there is chromosomal damage associated with HTLV-I proviral integration (Chieco-Bianchi et a/., 1988) , no consistent pattern of chromosomal translocation has been noted, again indicating that cis-activation of cellular oncogenes by viral or cellular promoters is not evident. Transactivation of cellular oncogenes by the tax protein is suspected to playa dominant role in the leukaemogenic process by activating a number of cellular genes, especially those associated with T-cell proliferation ( Table 2) . HTLV-I tax message has been identified in lymph node tissue of patients with ATL, providing evidence that tax is functioning in vivo (Greenberg et a/., 1990) .
The number and type of events leading from HTLV-I infection to the induction of ATL are uncertain. Okamoto et al. (1990) applied a mathematical (Weibull) model describing a multistep theory of carcinogenesis to the analysis of age-related increases of ATL. The age-dependent occurrence of ATL could be accurately described by this model for cumulative, multistep carcinogenesis, suggesting that ATL might be the end result of a number of critical somatic mutations. The number and types of events could not be estimated, although such events were thought to include abrogation of tumour suppressor genes or activation of oncogenes.
Antiviral strategies
Considerably less is known regarding antiviral strategies for HTLV-I than for HIV. Antiviral approaches for HTLV-I (Table 3) can be divided into those involving (1) chemical agents shown to inhibit viral replication or HTLV-I driven T-cell proliferation in vitro, and (2) biological agents such as interferons a, [3, and 'Yor IL-2 receptor-directed toxins.
Azidothymidine (3' azido-2' ,3'-deoxythymidine, AZT, zidovidine) inhibits both HIV-I and HTLV-I replication by inhibiting DNA elongation during retroviral DNA synthesis (Yarchoan et al., 1986a,b) . Earlier studies have shown that 2-,3'-deoxynucleosides have broad spectrum anti-retroviral activity against mammalian C-type and animallentiviruses (Dahlberg et a/., 1987) . Moreover, mouse viremia and retroviral disease could be suppressed by AZT (Ruprecht et al., 1986) . Matsushita et al. (1987) demonstrated that both AZT and 2,',3'-dideoxycytidine could inhibit the infectivity of HTLV-I for helper T cells in vitro. Moreover, a higher dose of AZT could inhibit HTLV-I proviral integration in an experimental model of HTLV-I associated adult T-ceilleukaerriia in rabbits (Isono et a/., 1990) . However, no clinical improvement was seen when AZT was administered to patients (30mg kg-1 days-1) with HAMITSP for 10d (Gout et al., 1989) .
Sulphated (glycyrrhizin sulphate, dextran sulphate, lentinam sulphate) and non-sulphated (E-P-LEM, extract of Lentinus edodes mycelia) polysaccharides have demonstrated antiviral activity for both HIV-I and HTLV-I in vitro. In this study Tochikura et al. (1989) found that both sulphated and non-sulphated polysaccharides inhibited cell-free viral infection (HIV-1, HIV-2) and cell-to-cell fusion or syncytium formation (HIV-I, HIV-2, and HTLV-I). These substances are thought to interfere with virusreceptor interaction or early stages of fusion induction.
Proviral methylation has played a role in controlling murine (Jahner et al., 1982) , avian (Conklin et a/., 1982) , and human (Bednarik et a/., 1987) retroviral transcription and is also associated with induction of DNA tumour virus (Desrosiers et al., 1979) . In vivo, HTLV-I proviral isolates are hypomethylated in the LTR and tax regions (Kitamura et al., 1985) . Conversely, proviral sequences in the low virus producing cell line MT-4 cells were found to be heavily methylated (Saggioro et al., 1990) .Treatment of MT-4 cells with the hypomethylating agent 5-azacytidine resulted in increased viral expression in vitro (Saggioro et al., 1990) . This study suggested that methylation might contribute to HTLV-Ilatency and reduced viral expression, although the effects of methylating agents on HTLV-I expression have not been reported. N-terminal myristoylation of HTLV-I and HIV-I gag precursors (Pr55 ga 9j is thought to facilitate viral assembly by associating the N-terminus of the gag precursor molecule with the internal lipid bilayer of the infected cell prior to maturational proteolysis and capsid formation. N-myristoyl glycinal diethylacetal, regarded as an inhibitor of protein N-myristoyl transferase, was found to prevent the myristoylation of HTLV-I p19 gag (Shoji et aI., 1988) . Blocking of capsid formation with anti-myristoylating agents may be important in preventing viral assembly.
The protein kinase inhibitor H7 [1-(5-isoquinolinyl-sulphonyl)-2-methylpiperazine] specifically blocked the accumulation of unspliced gag-pol mRNA transcripts by inhibiting the phosphorylation of rex . The levels of other singly (envelope)or doubly (tax) spliced viral transcripts were unaffected. Levels of gag protein were decreased with no apparent change in levels of envelope. It was concluded that phosphorylation of rex is required for proper regulation of the cytoplasmic accumulation of unspliced viral mRNA.
Selective killing of HTLV-I transformed cell lines was achieved with an n-pentyl ether of damavaricin Fc (DVFc), a derivative of streptovaricin C (Ito et aI., 1989) . N-pentyl DvFc appeared to exert its antiviral effect by increasing K+ve efflux from HTLV-I infected, but not uninfected T-cells.
Suramin, a complex urea derivative used in the treatment of trypanosomiasis and onchocerciasis, can inhibit the reverse transcriptase activity of a number of human and animal retroviruses including HIV-I and HTLV-I (DeClercq, 1979; Yarchoan and Broder, 1986a,b; Pesce et al., 1987) . Plasma levels of 100 JLg mr' were associated with decrease viral replication in primary cell cultures from HIV-I+ve patients, although no clinical improvement was noted (Yarchoan and Broder, 1986a,b) . Pesce et al. (1987) reported that low concentrations of suramin (10-100 JLg ml") could reduce HTlV-1 infection of cord blood lymphocytes (CBL). However, levels of viral mRNA were not reduced in infected CBL.
Interferons (INF) o , [3, and "y have been reported to reverse the immunosuppression induced by HTLV-I in human cord blood cultures (D'Onofrio et sl., 1990b) . Transient clinical improvement was reported in patients with CD4+ve, CD8-veATLreceiving INF-[3. However, the patient went into remission for 12 months and then relapsed with a fatal CD4+ve, CD8+ve leukaemia (Tamura et al., 1987) . Recombinant INF ct2, [3, 't can also inhibit the induction of HTLV-I antigens on normal peripheral blood leukocytes cocultured with HTLV-I infected cells and inhibit the proliferation of an ATL cell line (Koyama et al., 1990) .
Type A prostaglandins (PGA) have been shown to have anti-proliferative and antiviral properties (Santoro et aI., 1980 (Santoro et aI., , 1986 D'Onofrio et al., 1990a ). D'Onofrio et al. (1990b demonstrated that PGA, and 10,16-dimethyl-PGA 2-methyl ester could block proliferation of HTLV-I infected cord blood lymphocytes (CBL) and suppress the proliferation of an HTLV-l transformed cell line MT-2. The in vitro effects could not be attributed to direct antiviral activity or to recruitment of cell mediated immunity but rather to a direct suppression of proliferation of cells infected by HTLV-1. Rimsky et al. (1989) and Bohnlein et al. (1991) have defined a class of HTLV-I rex mutants that retain the capacity to localize to the cell nucleus but lack the ability to mediate rex-dependent HTLV-I env protein expression. Plasmids bearing transdominant rex mutant genes could competitively inhibit the function of wild-type HTLV-I rex as well as HIV-1 rev, resulting in a dose dependent inhibition of viral structural gene expression in COS cells. It was suggested that this form of viral gene repression could in theory be used as an 'intracellular immunogen' (Baltimore, 1988) to block viral replication, assuming that safe and efficient delivery systems could be developed.
Von Ruden and Gilboa (1989) used retroviral vectors to express antisense RNA encoding 5'LTR sequences essential for viral gene expression (5' splice site) and tRNA priming of reverse transcription. A second vector allowed expression of antisense RNA encoding the px (tax) region corresponding to the first kilobase of tax gene cDNA. Both vectors significantly reduced HTLV-I replication and immortalization of cord blood lymphocytes.
A monoclonal antibody (antl-Tac) directed to the a-chain of the human IL-2 receptor has been used with some success in the treatment of patients with HTLV-I induced ATL (Waldmann et al., 1988; Waldmann, 1991) . Anti-Tac is capable of blocking the binding of IL-2 to the IL-2 receptor a-chain. The IL-2 receptor is a useful target for antibody mediated therapy since it is not expressed on resting T-cells but is expressed on HTLV-I transformed ATL cells. Of 20 ATL patients treated by i.v, administration of anti-Tac, seven had remissions of which three were complete. A recombinant immunotoxin consisting of anti-Tac and a 40kd portion of Pseudomonas exotoxin (PE) is also being considered for use in humans as a treatment for ATL (Kreitman et al., 1990) .
.
Conclusions
The human T-lymphotropic viruses provide unique challenges for researchers and clinicians. Primary and secondary diseases associated with HTLV-l likely stem from cumulative events mediated by tax activation of the IL-2 autocrine loop and other cellular genes associated with growth and differentiation, such as interleukins 3, 4, and 6, granulocyte-macrophage colony stimulating factor, transforming growth factor f3 and vimentin. A cascade of lymphokines and cytokines triggered by the HTLV transactivator tax leads to aberrant immune activation and immunosuppression, resulting in a spectrum of disease manifestations from Kaposi's sarcoma, demyelination of long motor tracts in the spinal cord, chronic obstructive pulmonary disease, B-cell CLL and opportunistic infections similar to those seen in AIDS patients. Undefined events, possibly including activation of proto-oncogenes or inactivation of tumour suppressor genes, could lead from HTLV-I induced polyclonal proliferation to the emergence of a transformed cell line of monoclonal origin and leukaemia/lymphoma. Much progress has been made toward understanding mechanisms of HTLV-l transactivation, although little has translated into clinical application. IL-2 directed therapy has lead to clinical remission in some patients with ATL. Other types of potential therapeutic intervention strategies -transdominant repression of rex, inhibition of viral proteases or receptor blockade -remain to be developed. Perhaps the most effective antiviral strategies for prevention of HTLV infection and disease are already in place: screening of blood, curtailing breast feeding of children by HTLV-l+ve mothers, and public awareness of high-risk behaviours (needle-sharing, sexual promiscuity) that can lead to HIV and HTLV-I infection.
